pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ophthalmology · news · pharmadog
← back to Ophthalmology
News · Ophthalmology
406
stories
10h
STAT+: 7 burning questions about the FDA’s post-Overton future
stat
11h
FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
fda press
17h
GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
biospace
21h
Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna
fiercebiotech
1d
At Fierce’s London event, Big Pharmas tell biotechs to ‘be transparent’ to secure deals
fiercebiotech
1d
FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide
fda press
2d
J&J bets $2.2B on Ollin’s vision loss drug
biopharma dive
2d
ALDI Recalls Priano Protein Carbonara Tortelloni and Priano Protein Herb & Cheese Tortelloni Because Of Possible Health Risk
fda recalls
2d
J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
biospace
2d
J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B
endpoints
2d
Democrats settle on a message: ‘Medicare for More’
stat
2d
BeOne, Hengrui top list of China’s most powerful drugmakers
stat
2d
J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
fiercebiotech
3d
Emerging biotech hubs step up as innovation economics evolve
biospace
3d
Recon: FDA rejects ivonescimab for lung cancer indication; J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B
raps
5d
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
biospace
5d
Charles River pays $470M for 2 Frontage bioanalysis labs in Pennsylvania
fiercebiotech
5d
STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
stat
6d
FDA warns Chinese API manufacturers for refusing records requests, quality oversight
raps
6d
This Week: Senate HELP to vote on Overton, FDA shelves CNPV, and more
raps
6d
Sofinnova books biggest-ever $815M fund with an eye toward up-and-coming ‘global leaders’
fiercebiotech
6d
STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment
stat
6d
Opinion: I research MAHA and Black Americans. The relationship is complicated — and fascinating
stat
7d
Biopharma layoffs rise YOY in October but sharply trend down for 2026
biospace
7d
Why a fresh approach to targeting G protein-coupled receptors could treat a rare eye cancer
fiercebiotech
7d
STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
stat
7d
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
biopharma dive
7d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
7d
A new tactic in the war over out-of-network bills: Health care providers are suing employers
stat
7d
STAT+: Doctors on Kennedy’s influential preventive care panel have major conflicts of interest, filings reveal
stat
← prev
page 1 of 14
next →